~~What is c~~Claimed ~~is~~:

1. A composition comprising:

a) a non-neonate human effective amount of at least one specific binding molecule, or fragment thereof, obtained from an animal and that specifically binds to an antigen , wherein the specific binding molecule is selected from an immunoglobulin, antibody, ~~peptide, variable lymphocyte receptor, cell receptor, transfer factor, and~~ or a mixture thereof; and,

b) a carrier matrix comprising at least two components obtained from a nonhuman animal selected from the group consisting of enzymes, lactoferrin, transferrin, nonspecific immunoglobulins, cytokines, white blood cells, complement components, interferons, and fibronectin, wherein the carrier matrix comprises a matrix selected from the group consisting of, obtained from, isolated from, or derived from, serum, plasma, colostrum, or milk,

wherein the at least one specific binding molecule and the at least two components of the carrier matrix are obtained from different animals, and

wherein the effective amount is an amount effective for the treatment or prevention of undifferentiated diarrhea, undifferentiated pediatric diarrhea, traveler's diarrhea, rotavirus diarrhea, toxin-mediated diarrhea, cholera, C. difficile infection, dysentery, typhoid fever, peptic ulcers, or for gastrointestinal flora management.

2. The composition of claim 1 wherein the carrier matrix comprises a matrix selected from the group consisting of, obtained from, isolated from, or derived from~~, serum, plasma,~~ colostrum~~, milk, saliva, lymph fluid, mucous fluid, and lachrymal fluid~~.

3. The composition of claim 1 or claim 2, wherein the at least two components of the carrier matrix are selected from the group consisting of lysozyme, phospholipase, defensins, opsonins, nonspecific immunoglobulins, proline-rich polypeptides (PRPs), components of the complement system, beta-lysin, lactoferrin, transferrin, cytokines, interleukins, chemokines, interferons, TNF-alpha, fibronectin, leukocytes, white blood cells, phagocytes,

macrophages, monocytes, neutrophils, polymorphonuclear cells, dendritic cells, mast cells, eosinophils, basophils, natural killer (NK) cells, lymphokine activated killer (LAK) cells, elastase, cathepsin G, myeloperoxidase, NADPH oxidase, and combinations thereof.

4. The composition of any one of claims 1 to 3, wherein the antigen comprises a pathogen, a pathogen related toxin, a pathogen related adhesion element, undesirable strain, or a combination thereof.

5. The composition of claim 4, wherein the pathogen comprises a human or veterinary, enteric or gastrointestinal, pathogen causing gastroenteritis.

6. The composition of claim 4, wherein the pathogen is selected from the group consisting of: *Campylobacter jejuni, Salmonella, Salmonella enterica serovar Typhi, Shigella dystenteriae, Plesiomonas shigelloides, Escherichia coli* , enteropathogenic *E. coli,* enterotoxigenic *E. coli*, enteroaggregative *E. coli,* enteroinvasive *E. coli,* haemorrhagic *E. coli, Clostridium dificile, Yersinia enterocolitica, Vibrio cholerae* O1, *Vibrio* O139, Non-O1 *Vibrios, Vibrio parahaemolyticus, Aeromonas hydrophila, Clostridium perfringens,* enterohepatic Helicobacter, *Helicobacter pylori, Staphylococcus aureus, Klebsiella, Gardnerella* spp., *Neisseria gonorrhoeae, Chlamydiaceae trachomatis, Mycoplasma spp., Campylobacter jejuni, Trichomonas vaginalis*, herpes virus type 1, herpes virus type 2, *Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida krusei*, Group A *Streptococcus* spp., rotavirus, coronavirus, norovirus, calicivirus, enteric adenovirus, cytomegalovirus, astrovirus, *S. pneumoniae*, *H. influenzae*, *Neisseria gonorrhoeae*, herpes zoster virus, *Fusarium* spp., and *Acanthamoeba* spp.

7. The composition of claim 4, wherein the pathogen related toxin comprises an endotoxin or exotoxin.

8. The composition of claim 4, wherein the pathogen related adhesion element comprises adhesins, cadherins, cilia, fimbrillae, a viral adhesion structure, or a combination thereof.

9. The composition of any one of claims 1 to 8, wherein the composition comprises an amount effective for the treatment or prevention of undifferentiated diarrhea, traveler's diarrhea, rotavirus diarrhea, toxin-mediated diarrhea, cholera, ~~C. difficile infection, dysentery,~~ typhoid fever, ~~peptic ulcers,~~ or for gastrointestinal flora management.

10. The composition of claim 9, wherein the undifferentiated diarrhea is pediatric undifferentiated diarrhea.

11. The composition of any one of claims 1 to 8, wherein the composition comprises an amount effective for conferring passive immunity to a subject.

12. The composition of any one of claims 1 to 11, wherein the specific binding molecule is an antibody or a fragment thereof.

13. The composition of claim 12, wherein the antibody or fragment thereof is ~~is~~ selected from a polyclonal antibody or a monoclonal antibody.

14. The composition of claim 12, wherein the antibody is an IgG.

15. The composition of claim 12, wherein the antibody is IgY.

16. The composition of any one of claims 12 to 15, wherein the antibody is a polyclonal antibody.

17. The composition of any one of claims 1 to 16, wherein the carrier matrix is colostrum.

18. The composition of claim 17, wherein the colostrum is non-hyperimmune bovine colostrum.

19. The composition of claim 17 or claim 18, wherein the colostrum is dried full-fat bovine colostrum.

~~19.~~20. The composition of any one of claims 1 to 19~~claims 1-18~~, wherein the specific binding molecule is in a solid form.

~~20.~~21. The composition of claim 20~~claim 19~~, wherein the specific binding molecule is crystalline.

~~21.~~22. The composition of any one of claims 1 to 21~~to 20~~, wherein the carrier matrix is in a solid form.

~~22.~~23.The composition of any one of claims 1 to 21 ~~to 20~~ further comprising a pharmaceutically acceptable diluent, binder, excipient, lubricant, sweetening agent, flavoring agent, wetting agent, or absorbent.

~~23.~~24. A method for preparing the composition of any one of claims 1 to 23~~to 22~~, comprising

(a) obtaining at least one specific binding molecule or fragment thereof from an animal that binds to a specific antigen, wherein the specific binding molecule is selected from an immunoglobulin, antibody, ~~peptide, cell receptor, variable lymphocyte receptor, transfer factor, and~~ or a mixture thereof;

(b) obtaining at least one carrier matrix, comprising at least two components

obtained from a nonhuman animal selected from the group consisting of enzymes, lactoferrin, transferrin, nonspecific immunoglobulins, cytokines, white blood cells, complement components, interferons, and fibronectin, wherein the carrier matrix comprises a matrix selected from the group consisting of, obtained from, isolated from, or derived from, serum, plasma, colostrum, or milk;

(c) preparing a solid form of the carrier matrix and of the specific binding molecule or fragment thereof ; and

(d) mixing the solid form of the carrier matrix with the solid form of the specific binding molecule or fragment thereof .

~~24.~~25. The method of claim 24~~claim 23~~, wherein the specific binding molecule or fragment thereof contains a non-neonate human effective amount of the specific binding molecule or fragment thereof.

~~25.~~26. The method of ~~claim 23 or~~ claim 24 or claim 25, wherein the matrix ~~comprises a matrix selected from the group consisting of~~ colostrum~~, milk, serum, plasma, saliva, lymph fluid, mucous fluid, and lachrymal fluid~~.

27. The method of any one of claims 24 to 26~~or claim 25~~, wherein the matrix comprises a matrix consisting of non-hyperimmune bovine colostrum.

28. The method of claim 26 or claim 27 wherein the colostrum is full-fat bovine colostrum

~~26.~~29. The method of any one of claims 24 to 28~~23 to 25~~, wherein the at least two components of the carrier matrix are selected from the group consisting of lysozyme, phospholipase, defensins, opsonins, nonspecific immunoglobulins, proline-rich polypeptides (PRPs), components of the complement system, beta-lysin, lactoferrin, transferrin, cytokines, interleukins, chemokines, interferons, TNF-alpha, fibronectin, leukocytes, white blood cells,

phagocytes, macrophages, monocytes, neutrophils, polymorphonuclear cells, dendritic cells, mast cells, eosinophils, basophils, natural killer (NK) cells, lymphokine activated killer (LAK) cells, elastase, cathepsin G, myeloperoxidase, NADPH oxidase, and combinations thereof.

~~27.~~30. A composition of any one of claims 1 to 23 ~~to 22~~ for the management of pathogenic or undesirable strain of microorganisms in a mammal.

~~28.~~31. The composition of ~~claim 27~~ claim 30, wherein the mammal is a human.

~~29.~~32. The composition of ~~claim 28~~ claim 31, wherein the human is not a neonate.

~~30.~~33. The composition of any one of claims ~~27 to 29~~ 30 to 32 wherein the pathogenic micororganism is selected from the group consisting of: *Campylobacter jejuni, Salmonella, Salmonella enterica serovar Typhi, Shigella dystenteriae, Plesiomonas shigelloides, Escherichia coli,* enteropathogenic *E. coli,* enterotoxigenic *E. coli*, enteroaggregative *E. coli,* enteroinvasive *E. coli,* haemorrhagic *E. coli, Clostridium dificile, Yersinia enterocolitica, Vibrio cholerae* O1, *Vibrio* O139, Non-O1 *Vibrios, Vibrio parahaemolyticus, Aeromonas hydrophila, Clostridium perfringens,* enterohepatic Helicobacter, *Helicobacter pylori, Staphylococcus aureus, Klebsiella*, *Gardnerella* spp., *Neisseria gonorrhoeae, Chlamydiaceae trachomatis, Mycoplasma spp., Campylobacter jejuni, Trichomonas vaginalis*, herpes virus type 1, herpes virus type 2, *Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida krusei*, Group A *Streptococcus* spp., rotavirus, coronavirus, norovirus, calicivirus, enteric adenovirus, cytomegalovirus, astrovirus, *S. pneumoniae*, *H. influenzae*, *Neisseria gonorrhoeae*, herpes zoster virus, *Fusarium* spp., and *Acanthamoeba* spp.

~~31.~~34. A composition of any one of claims 1 ~~to 22~~ to 23 useful as a nutritional composition for administering to a subject in need thereof, wherein the subject is afflicted with a disease

that creates special dietary needs wherein the disease is selected from the group consisting of pediatric diarrhea, Crohn's disease, and ulcerative colitis.